LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus

Bibliography

• LIPSKY PE: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. (2001) 2:764-766.
   PubMed Web of Science ®Google Scholar
• URAMOTO KM, MICHET CJ, THUMBOO J, SUNKU J, O’FALLON WM, GABRIEL SE: Trends in the incidence and mortality of systemic lupus erythematosus. Arthritis Rheum. (1999) 42:46-50.
   PubMed Web of Science ®Google Scholar
• CERVERA R, KHAMASTA MA, FONT J et al., EUROPEAN WORKING PARTY ON SYSTEMIC LUPUS ERYTHEMATOSUS: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (2003) 82:299-308.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, MORONI G: Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus (1998) 7:635- 638.
   PubMed Web of Science ®Google Scholar
• MOSCA M, BENCIVELLI W, NERI R et al.: Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. (2002) 61:1502-1509.
   PubMed Web of Science ®Google Scholar
• AUSTIN HA III, KLIPPEL JH, BALOW JE et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. NEJM (1986) 314:614-619.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, AUSTIN HA III, VAUGHN EM et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 340:741- 745.
   PubMed Web of Science ®Google Scholar
• HOUSSIAU FA, VASCONCELOS C, D’CRUZ D et al.: Immunosuppressive therapy in lupus nephritis the euro-lupus nephritis trial, a randomised trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. (2002) 46:2121-2131.
   PubMed Web of Science ®Google Scholar
• MOK CC, YING KY, NG WL et al.: Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am. J. Med. (2006) 119:355.e25-355.e33.
   PubMed Web of Science ®Google Scholar
• ILLEI GG, AUSTIN HA III, CRANE M et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Int. Med. (2001) 135:248-257.
   PubMed Web of Science ®Google Scholar
• ILLEI GG, TAKADA K, PARKIN D et al.: Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. (2002) 46:995-1002.
   PubMed Web of Science ®Google Scholar
• MOK CC, YING KY, TANG S et al.: Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. (2004) 8:2559-2568.
   Google Scholar
• BONGU A, CHANG E, RAMSEY-GOLDMAN R: Can morbidity and mortality of SLE be improved? Best Pract. Res. Clin. Rheumatol. (2002) 16:313-332.
   PubMed Web of Science ®Google Scholar
• KATSIFIS GE, TZIOUFAS AG: Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus (2004) 13:673-678.
   PubMed Web of Science ®Google Scholar
• SCHATTNER A, NAPARSTEK Y: The future of the treatment of systemic lupus erythematosus. Clin. Exp. Rheumatol. (2005) 23:254-260.
   PubMed Web of Science ®Google Scholar
• O’NEIL SG, SCHRIEBER L: Immunotherapy of systemic lupus erythematosus. Autoimmun. Rev. (2005) 4:395-402.
   Google Scholar
• DOOLEY MA, GINZLER EM: Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum. Dis. Clin. North Am. (2006) 32:91-102.
   PubMed Web of Science ®Google Scholar
• LOONEY RJ, ANOLIK J, SANZ I: New therapies for systemic lupus erythematosus: cellular targets. Rheum. Dis. Clin. North Am. (2006) 32:201-215
   PubMed Web of Science ®Google Scholar
• KOURBETI IS, BOUMPAS DT: Biological therapies of autoimmune diseases. Curr. Drug Targets Inflamm. Allergy (2005) 4:41-46.
   PubMedGoogle Scholar
• KIROU KA, SALMON JE, CROW MK: Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum. Dis. Clin. North Am. (2006) 32:103-119.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, ARINGER M: New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol. (2005) 19:859-878.
   PubMed Web of Science ®Google Scholar
• WALLACE DJ, TUMLIN JA: LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus (2004) 13:323-327.
   PubMed Web of Science ®Google Scholar
• RIBOLDI P, GEROSA M, MORONI G et al.: Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity (2005) 38:39-45.
   PubMed Web of Science ®Google Scholar
• LINNIK MD, HU JZ, HEILBRUNN KR et al.: Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. (2005) 52:1129-1137.
   PubMed Web of Science ®Google Scholar
• FURIE RA, CASH JM, CRONIN ME et al.: Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. (2001) 28:257-265.
   PubMed Web of Science ®Google Scholar
• CARDIEL MH: Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. Expert Opin. Investig. Drugs (2005) 141:77-88.
   Google Scholar
• HARTLEY SB, COOKE MP, FULCHER DA et al.: Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell (1993) 72:325-335.
   PubMed Web of Science ®Google Scholar
• MCNEELY PA, IVERSON GM, FURIE RA et al.: Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus (2001) 10:526-532.
   PubMed Web of Science ®Google Scholar
• LINNIK M, STAINES NA, BERDEN J, ISENBERG DA: Workshop report on some new ideas about the treatment of systemic lupus erythematosus. Lupus (2002) 11:793-796.
   PubMed Web of Science ®Google Scholar
• WEISMAN MH, BLUESTEIN HG: A pilot study of ljp 394, a novel therapeutic agent for the treatment of systemic lupus erythematosus. Arthritis Rheum. (1995) 38(Suppl.): S302.
   Google Scholar
• CASH J, CRONIN M, KATZ R et al.: A dose-ranging study of LJP 394, a novel therapeutic agent for the treatment of systemic lupus erythematosus. Scand. J. Rheumatol. (1996) 106(Suppl.): 9.
   Google Scholar
• HEPBURN B, FURIE R, CASH J et al.: Reduction of anti-dsDNA antibodies using LJP 394 in patients with lupus. Arthritis Rheum. (1996) 39(Suppl.): S307.
   Google Scholar
• ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum. (2003) 48:442- 454.
   PubMed Web of Science ®Google Scholar
• CARDIEL MH, TUMLIN JA, FURIE RA et al.: Clinical efficacy results from a RCT of LJP 394 in SLE patients with history of renal disease. Arthritis Rheum. (2003) 48(Suppl.):S582-S583.
   PubMedGoogle Scholar
• STRAND V, Aranow C, Cardiel MH et al.: Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomised clinical trial comparing LJP 394 treatment with placebo. Lupus (2003) 12:677-686.
   PubMed Web of Science ®Google Scholar
• BOMBARDIERI S, CARDIEL MA, TUMLIN JA et al.: Summary of safety results from studies of LJP 394 in SLE patients. Ann. Rheum. Dis. (2004) 63(Suppl.1): 216.
   PubMedGoogle Scholar